Expert Advice 8 Oct 2019 Why Good Teamwork is Key to Biotech Success Teamwork is important throughout the development of a company, but never more so than in the early stages of a startup. Charlotte Edenius, co-founder and VP Business and Clinical development at Gesynta Pharma in Sweden, knows this well. With more than 20 years experience working in the industry, she knows how important it is for biotech leaders […] October 8, 2019 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 7 Oct 2019 UK Biotech Launches with €30M Series A to Treat Autoimmune Disease MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […] October 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 4 Oct 2019 This Biotech Genetically Engineers Trees to Produce Biofuels The Swedish company SweTree Technologies is developing genetically engineered trees as environmentally friendly alternative sources of fuel. Mission: To improve the yield and robustness of tree crops such as spruce and eucalyptus using selective breeding and genetic engineering. This would help to boost the production of products such as biofuels and wood from each tree. […] October 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2019 ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on the specific market situation. Its withdrawal is likely due to slumps in European and US stock markets seen earlier this week caused by drops in […] October 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 2 Oct 2019 Engineered Crop Plants Produce Fat Molecules for Formula Milk A team from the Rothamsted Research center, UK, has developed plants capable of mass-producing fat molecules resembling those in human breast milk. The scientists modified the way a type of oilseed plant generates fat molecules by introducing a mutation that changed the location within the cell of an enzyme responsible for processing fat. As a […] October 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2019 RNA Therapies, Immunotherapies and Cancer Tests Showcased in Spain Biotech companies around the world gathered in Barcelona, Spain, to present breakthroughs in cancer diagnostics and treatments such as cell therapies and cancer vaccines. Here’s our take on the most interesting offerings from the European crop. Barcelona is the home of Gaudi and Barcelona Football Club. Over the last few days, it was also the […] October 2, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Opinion 30 Sep 2019 Can European Biotech Companies Afford Not to Work with China? In the current trade standoff between the US and China, Europe has a golden opportunity to gain a competitive advantage. At every healthcare conference I’ve been to recently in the US or Europe, the same question is being debated on panels: Should you or should you not have a China strategy as a biotech CEO? […] September 30, 2019 - 4 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […] September 30, 2019 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 €20M Series A Launches Cancer Immunotherapy Biotech in Denmark The Danish company STipe Therapeutics has been launched with a €20M Series A to develop immunotherapy drugs that sensitize the innate immune system against cancer. STipe Therapeutics was spun out from Aarhus University, Denmark, last year with a small grant, and has now completed its full launch with this Series A. The round was co-led […] September 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 30 Sep 2019 Taking Your Product Forward Against All Odds Having to let go of your flagship product after years of development is not easy. Nor is fundraising for another product after a major partner backs out — a challenge that Angela Hildreth had to confront when she joined the British company Futura Medical as Finance Director last year. Angela Hildreth had never worked in […] September 30, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 27 Sep 2019 This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […] September 27, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2019 Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the […] September 26, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email